Cover Image

The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus

Amylin is a 37-amino-acid peptide related to CGRP and calcitonin. It is co-secreted with insulin from pancreatic β-cells. Amylin is deficient with type 1 diabetes mellitus. To study the in vivo effects of amylin in humans, diabetic patients are an adequate model of chronic amylin deficiency. We inve...

Full description

Saved in:
Bibliographic Details
Main Authors: Borm, Anne Katrin (Author) , Klevesath, Martina (Author) , Borcea, Valentin (Author) , Kasperk, Christian (Author) , Seibel, Markus J. (Author) , Wahl, Peter (Author) , Ziegler, Reinhard (Author) , Nawroth, Peter Paul (Author)
Format: Article (Journal)
Language:English
Published: 1999
In: Hormone and metabolic research
Year: 1999, Volume: 31, Issue: 8, Pages: 472-475
ISSN:1439-4286
DOI:10.1055/s-2007-978777
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1055/s-2007-978777
Verlag, lizenzpflichtig, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/s-2007-978777
Get full text
Author Notes:A.K. Borm, M.S. Klevesath, V. Borcea, C. Kasperk, M.J. Seibel, P. Wahl, R. Ziegler, P.P. Nawroth
Description
Summary:Amylin is a 37-amino-acid peptide related to CGRP and calcitonin. It is co-secreted with insulin from pancreatic β-cells. Amylin is deficient with type 1 diabetes mellitus. To study the in vivo effects of amylin in humans, diabetic patients are an adequate model of chronic amylin deficiency. We investigated the effect of a 12 months pramlintide therapy (amylin analogue) on bone metabolism in patients with type 1 diabetes mellitus.
Item Description:Elektronische Reproduktion der Druck-Ausgabe, 20. April 2007
Gesehen am 09.06.2021
Physical Description:Online Resource
ISSN:1439-4286
DOI:10.1055/s-2007-978777

Similar Items